Compare Extra Space Storage, Inc. (EXR) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Eli Lilly And Co — how do they compare? Extra Space Storage, Inc. trades at $133.93 (market cap $28.12B), while Eli Lilly And Co trades at $1,173.5 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 37× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 108 Days and Eli Lilly And Co for 93 Days on average.
| EXR | LLY | |
|---|---|---|
Market Cap | $28.12B | $1.04T |
Volume | 2,595,579 | 3,064,878 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $1.28K |
52-Week Low | $126.67 | $799.57 |
Typical Hold Time | 108 Days | 93 Days |
Enterprise Value | $41.84B | $1.09T |
Dividend Yield | 4.87% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXR trades at $133.3, up 1.21% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue grew to $3.38B in 2025, and net income margin improved to 27.79%. Analyst consensus is split evenly between Buy and Hold, with a $158.33 price target suggesting upside. Recent news highlights leadership transition and institutional buying interest.
Outlook is mixed: solid fundamentals and analyst targets support growth, but technical weakness and high valuation ratios pose risks. Investors should weigh steady cash flow and dividend yield against debt levels and market sentiment shifts ahead of earnings.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
